Ori Industries and VMware Deliver Edge Advantage for Enterprises
4.10.2021 08:00:00 EEST | Business Wire | Press release
London based edge computing pioneer Ori Industries is partnering with VMware, Inc. (NYSE: VMW), a leading innovator in enterprise software, to facilitate enterprise implementation of edge computing across hybrid, telco and multi-cloud deployments. The interoperability of VMware Telco Cloud Platform and Ori Global Edge reduces complexity, increases service velocity, and manageability of cloud-native service delivery at the edge.
According to Gartner 1, “edge computing is entering the mainstream”; however, many enterprises struggle with their existing cloud deployments proving to be a barrier to edge adoption. Ori and VMware’s partnership will help overcome this challenge by offering a fully functioning edge platform that connects to any cloud environment from telco to hybrid to multi-cloud.
Ori Global Edge on VMware Telco Cloud Platform is a managed cloud service offering that delivers a multi-connected edge by using multiple points of presence (PoP) that connect to the telco and communications service provider (CSP) infrastructure on one end and different clouds on the other end. The solution2 enables CSPs to offer multi-access edge computing (MEC) capabilities, which allow them to greater monetize their 5G offering to the enterprise. At the same time, it allows them to reduce their backhaul costs through intelligent workload placement.
Customers will benefit from service availability at the edge with low latency, highly-available applications generating and processing data locally without overhead for data transfer back to the cloud for processing. Extracting, analysing and using data at the edge permits a new class of enterprise services for enhanced customer experience.
Stephen Spellicy, vice president of product marketing, Service Provider and Edge, VMware, said, “Enterprises are looking for new ways to engage customers and deliver next-generation experiences. That means having the right application deployed where the user is. Edge computing is the final piece of the puzzle and working with Ori Industries’ multi-access edge computing platform will give mutual customers the ability to deploy a solution that helps cover all their environments – whether telco, hybrid, multi-cloud or edge – to meet their business needs.”
Douglas Mancini, CCO at Ori Industries said “Edge computing offers enterprises immense opportunities to not only deliver new innovative solutions but also reinvent their existing infrastructure in a more efficient way: Enterprises have learned that a pure cloud-first model has failed to deliver the expected value or agility, and Ori Global Edge is helping do just that. By combining our edge computing expertise with VMware Telco Cloud Platform and multi-cloud leadership, we are able to offer enterprises a way of harnessing the power of edge and reaping the benefits of being able to use data near to its creation.”3
For more information visit: https://ori.co/.
About Ori Industries
Ori Industries is laying the foundation for the global rollout of edge computing services. The company’s edge platform simplifies workload provisioning across public, Telco, hybrid, and multi-cloud infrastructure to support countless new and emerging enterprise use cases. Ori Industries is based in London with a global workforce. For more information, please visit https://www.ori.co/.
VMware and VMware Telco Cloud Platform are registered trademarks or trademarks of VMware, Inc. or its subsidiaries in the United States and other jurisdictions.
1
https://www.gartner.com/en/documents/3992656/2021-strategic-roadmap-for-edge-computing
2 Solution Overview: https://www.vmware.com/content/dam/digitalmarketing/vmware/en/pdf/microsites/telco/vmware-ori-solution-brief.pdf
3 Video Interview: https://www.youtube.com/watch?v=R-fUFNElWzo
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20211003005023/en/
Contact information
Media Contact for Ori Industries:
iMiller Public Relations
Mia Hinterwaldner
Tel: 866.307.2510
Email: ori@imillerpr.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
WHOOP and Samuel Ross MBE Unveil Layer 2 of PROJECT TERRAIN26.10.2026 12:30:00 EET | Press release
WHOOP, the human performance brand, today announced Layer 2 of PROJECT TERRAIN, its multiyear collaboration with British designer Samuel Ross MBE and his design atelier, SR_A. Building on the sold out debut collection launched in March 2026, Layer 2 expands PROJECT TERRAIN to its next season connecting lifestyle and performance for movement, adaptability and zone based training. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261026029587/en/ WHOOP and Samuel Ross MBE Unveil Layer 2 of PROJECT TERRAIN While the first PROJECT TERRAIN collection harnessed dense cities and modern training grounds, Layer 2 explores performance through material, silhouette and tactility. Drawing on the textures, conditions, and flux of the natural world, the collection introduces a newly developed system of WHOOP bands, Italian technical apparel, outerwear, and accessories designed to move between urban and outdoor settings. Performance extends be
Bleeding gums? Don't ignore the warning signs – the first stage of gum disease can be reversed26.10.2026 12:28:00 EET | Press release
Gums bleeding when brushing can happen to any of us, and it is easy to ignore. But blood in the sink is a sign that something is not right with your mouth. Bleeding gums often indicate gingivitis, the earliest and most common form of gum disease. The good news: gingivitis can be reversed with proper oral hygiene. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261022835650/en/ Oral-B iO Left untreated, gingivitis can progress into periodontitis, a more severe stage of gum disease that can only be managed, not reversed, and can lead to losing teeth over time. Healthy gums matter beyond the mouth, too. Oral health and systemic health are deeply interconnected, with inflammation and bacteria from oral diseases contributing to conditions such as heart disease, diabetes and dementia. "Gums bleeding when brushing can happen to any of us. When they do, it shouldn't be ignored," said Eva Castro Perea, who holds a degree in dentistry
Merz Therapeutics Presents New Phase 2 PaiNT Data in Peripheral Neuropathic Pain at IASP 202626.10.2026 09:00:00 EET | Press release
Merz Therapeutics, a leading player in neurology-focused specialty pharma, today announced the presentation of new clinical and translational research in peripheral neuropathic pain (PNP) at the International Association for the Study of Pain (IASP) 2026 World Congress in Bangkok, Thailand, taking place from 26 to 30 October. The research spans new Phase 2 findings on incobotulinumtoxinA in postherpetic neuralgia (PHN) and post-surgical/post-traumatic neuropathic pain (PS/PTNP), as well as preclinical studies exploring potential biological mechanisms involved in effects of incobotulinumtoxinA on PNP models, highlighting Merz Therapeutics’ growing presence in neuropathic pain. In the PHN population of the Phase 2 PaiNT trial, results over 20 weeks favored incobotulinumtoxinA versus placebo treatment. In an exploratory analysis of average daily pain (ADP) intensity, the greatest difference between treatment groups was observed at Week 6 (adjusted mean difference, −1.14 points; p=0.0488).
BeOne Presents Compelling Data in Hard-to-Treat Liver and Lung Cancers at ESMO 202624.10.2026 11:15:00 EEST | Press release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from multiple differentiated investigational medicines across its priority solid tumor disease areas at the European Society for Medical Oncology (ESMO) Congress 2026 (October 23–27, Madrid). The presentations span gastrointestinal, lung, and breast cancers, and reflect the growing momentum of BeOne’s solid tumor franchise. Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “At ESMO, we are showing how our strategy of matching the right modality to disease biology is translating into meaningful clinical progress. Our GPC3 x 4-1BB bispecific antibody continues to be well tolerated and demonstrates durable activity with longer follow up in patients with heavily pre-treated hepatocellular carcinoma, while the first clinical data from our brain-penetrant PRMT5 inhibitor and CEA-targeting ADC expand our innovation in non-small cell lung cancer. Alongsi
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 20:42:00 EEST | Press release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom